Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Els Keyaerts, Leen Vijgen, Piet Maes, Johan Neyts, Marc Van Ranst*

Rega Institute for Medical Research, University of Leuven, 3000 Leuven, Belgium

Received 11 August 2004
Available online 28 August 2004

Abstract

We report on chloroquine, a 4-amino-quinoline, as an effective inhibitor of the replication of the severe acute respiratory syndrome coronavirus (SARS-CoV) in vitro. Chloroquine is a clinically approved drug effective against malaria. We tested chloroquine phosphate for its antiviral potential against SARS-CoV-induced cytopathicity in Vero E6 cell culture. Results indicate that the IC50 of chloroquine for antiviral activity (8.8 ± 1.2 µM) was significantly lower than its cytostatic activity; CC50 (261.3 ± 14.5 µM), yielding a selectivity index of 30. The IC50 of chloroquine for inhibition of SARS-CoV in vitro approximates the plasma concentrations of chloroquine reached during treatment of acute malaria. Addition of chloroquine to infected cultures could be delayed for up to 5 h postinfection, without an important drop in antiviral activity. Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

© 2004 Elsevier Inc. All rights reserved.

Keywords: SARS-CoV; Severe acute respiratory syndrome; Coronavirus; Chloroquine; Antiviral activity

Severe acute respiratory syndrome (SARS) has recently emerged as a new highly contagious human disease with a major impact all over the world [1]. The global SARS epidemic started in the Guangdong Province in southern China, where several cases of atypical pneumonia of unknown etiology were reported at the end of November 2002. A novel member of the Coronaviridae family has been identified as the causative agent of SARS [2–7]. Three other human coronaviruses (HCoV) OC43, 229E, and the recently characterized NL63 are important causes of upper respiratory tract illnesses. In late fall and winter they are responsible for approximately one-third of the common colds.

During the epidemic in 2003, treatment of SARS was empirical due to the limited understanding of this new disease. Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may be of benefit as antiviral therapy, when given in the early phase of the illness [8,9]. The role of interferon and systemic steroids in preventing immune-mediated lung injury requires further investigation [10,11].

Since the epidemic, a lot of effort has been put into antiviral research to find compounds effective against SARS-CoV. Glycyrrhizin (an active component of liquorice roots), niclosamide (an antihelminthic drug), nelfinavir (a human immunodeficiency deficiency virus (HIV) protease inhibitor), and SNAP (a nitric oxide donor) were reported to have an antiviral effect against SARS-CoV [12–15].

Savarino et al. [16] hypothesized that chloroquine might be of some use for the clinical management of SARS. Chloroquine is known as an antimalarial agent and elicits also antiviral effects against several viruses including HIV type 1 (HIV-1) [17–19], hepatitis B virus [20], herpes simplex virus type 1 [21], and HCoV-229E [22]. The antiviral effects of chloroquine against HIV type 1 replication are currently being tested in clinical
trials [16]. Besides a direct antiviral effect, chloroquine is endowed with immunomodulatory activity, suppressing the production and release of tumour necrosis factor and interleukin 6, which mediate the inflammatory complications of several viral diseases [16].

In this study, we evaluate chloroquine for its potential to protect against SARS-CoV infection in vitro.

Materials and methods

Cell culture and virus. The SARS-CoV Frankfurt 1 strain was kindly provided by Prof. Dr. H. F. Rabenau from the Johann Wolfgang Goethe University, Frankfurt, Germany. Vero E6 cells were propagated in minimal essential medium (MEM; Gibco, Life Technologies, Rockville, MD) supplemented with 10% fetal calf serum (FCS, Integro, Zaandam, The Netherlands), 1% L-glutamine (Gibco, Life Technologies, Rockville, MD), and 1.4% sodium bicarbonate (Gibco, Life Technologies, Rockville, MD). Virus-infected cells were maintained at 37 °C in 5% CO2 in MEM supplemented with 2% FCS.

Compounds. We tested chloroquine phosphate (7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline phosphate, Alpha pharma, Braine-l’Alleud, Belgium) and interferon β-1a (Avonex, Biogen) was used as a positive control.

Real-time quantitative RT-PCR. A real-time quantitative RT-PCR (Taqman) was designed in the putative nsp11 region in the replicase 1B domain of the SARS-associated coronavirus (SARS-CoV) genome forward primer (SARS-FP: 5’-CACCAGAGAAAGCTATTCC-3’), MGB probe (SARS-TP: FAM-5’-TGGTGATTGGCCT-3’-NFQ-MGB), and reverse primer (SARS-RP: 5’-TTGATGACAGCCTCTACATC-3’). A 25 μl RT-PCR was carried out using 5 μl of extracted RNA or standard cRNA, 12.5 μl TaqMan One-Step RT-PCR Master Mix containing ROX as a passive reference (Applied Biosystems, Foster City, CA, USA), 900 nM forward and reverse primers, and 150 nM MGB probe. Amplification and detection were performed in an ABI PRISM 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) under the following conditions: an initial reverse transcription at 48 °C for 30 min, followed by PCR activation at 95 °C for 10 min and 45 cycles of amplification (15 s at 95 °C and 1 min at 60 °C). During amplification, the ABI PRISM sequence detector monitored real-time PCR amplification by quantitative analysing fluorescence emissions. The reporter dye (FAM) signal was measured against the internal reference dye (ROX) signal to normalize for non-PCR-related fluorescence fluctuations occurring from well to well. The threshold cycle represented the refraction cycle number at which a positive amplification was measured, and was set at 10 times the standard deviation of the mean baseline emission calculated for PCR cycles 3–5.

Construction of cRNA standards. The TaqMan SARS-CoV forward primer was modified with a T7-promoter sequence at the 5’-end (SARS-FPT7: 5’-TAATACGACTCATATAGGGAAATACTCCGC GAAGAGACTATTCC-3’). PCR products amplified with the modified primer pairs were quantified spectrophotometrically at 260 nm. Two hundred nanograms of PCR product was used for in vitro transcription (MEGAshortscript T7 kit, Ambion, Austin, TX, USA) performed at 37 °C for an overnight period in a 20 μl reaction mix containing 2 μl reaction buffer, 2 μl of each NTP, and 2 μl enzyme mix. The cDNAs were digested by removing 2 U of RNase-free DNase I for 15 min at 37 °C. The cRNAs were precipitated by adding 3 μl of 3 M NaOAc and 60 μl of 96% EtOH and a subsequent incubation at −20 °C for 30 min. After 15 min of centrifugation at 13,000 rpm, supernatant was removed and 500 μl of 70% EtOH was added. After another 5 min centrifugation at 13,000 rpm, supernatant was removed and the pellet was dissolved in 200 μl RNase free H2O (Sigma–Aldrich NV, Bornem, Belgium) and stored at −80 °C. Quantification of cRNAs was performed spectrophotometrically at 260 nm. The measurements of cRNA concentration were performed in duplicate and then converted to the molecule number [23].

Antiviral assay. Antiviral activity and cytotoxicity measurements were based on the viability of cells that had been infected or not infected with 100 CCID50 (50% cell culture infective doses) of the SARS-CoV in the presence of various concentrations of the test compounds. Three days after infection, the number of viable cells was quantified by a tetrazolium-based colorimetric method, in which the reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium (MTS) dye (CellTiter 96 AQueous One Solution kit, Promega, The Netherlands) was measured against the internal reference dye (ROX) signal to an insoluble coloured formazan was measured in a spectrophotometer (Multiskan EX, Thermo Labsystems, Belgium) at 492 nm [24,25].

Time-of-addition assay. Subconfluent monolayers of Vero E6 cells in 96-well plates were infected with 100 CCID50 SARS-CoV. After 20 min of adsorption, cell monolayers were washed five times with MEM. Chloroquine was added at a concentration 12-fold above the IC50 (8.8 μM) in triplicate, at the time of infection or at different time points thereafter. Eight hours after infection (a time at which the first viral cycle has been completed), cell supernatants were collected, viral RNA was extracted, and the antiviral activity was determined by using the quantitative RT-PCR described above.

Virus yield assay. After incubation of the virus-infected Vero E6 cells with different concentrations of the test compounds, under the appropriate conditions, supernatants containing free viruses were subjected to quantitative RT-PCR. Virus titers were determined on day 1 and day 3 postinfection.

Results and discussion

In this study we report the in vitro antiviral activity of chloroquine against SARS-CoV Frankfurt 1 strain infection. Cytotoxicity in Vero E6 cells was measured in parallel with the antiviral activity. This experiment, done in quadruplicate, was repeated three times, and representative results are shown in Fig. 1.

In the virus yield assay, where viral RNA was quantified one and three days postinfection, no significant replication was observed after one day when the cells were treated with 4 μM chloroquine. To inhibit virus replication by 99% three days postinfection, 16 μM chloroquine was needed (Fig. 2).

To obtain initial insight into the stage in the viral replication cycle at which chloroquine may exert its antiviral activity, a time-of-drug-addition assay was elaborated. Vero E6 cells were infected with 100 CCID50 SARS-CoV. One virus replication cycle takes 5–6 h [26]. We therefore quantitated the effect on viral replication at 8 h postinfection, i.e., a time point at which progeny virus in the supernatant is solely derived from the first replication cycle. The compound proved equally active when added during adsorption or at 1 h after infection. This indicates that the virus does likely not interfere
with the early steps of viral replication, i.e., attachment or penetration. At later time points a gradual loss of the antiviral activity of chloroquine was noted. (Fig. 3).

The IC$_{50}$ of chloroquine inhibition of SARS-CoV replication in Vero E6 cells, 8.8 $\mu$M, is below (1000-fold) the plasma concentrations of chloroquine that are reached in human plasma, following treatment with chloroquine (for acute malaria) at a dose of 25 mg/kg over three days [27]. The dose of chloroquine used for the treatment of rheumatoid arthritis (3.6 mg/kg) generates plasma chloroquine concentrations of 1–3 $\mu$M, which is in the same concentration range as the IC$_{50}$ for inhibition of SARS-CoV [28].

Our results show that chloroquine inhibits the replication of SARS-CoV in Vero E6 cells. Since immunopathological factors may play a significant role in SARS-CoV, it will be of interest to further study whether chloroquine is also effective in terms of modulation of inflammatory responses to SARS-CoV infections.

Chloroquine is given prophylactically at a dose of 300 mg/week to people travelling to malaria endemic areas. If SARS re-emerges, chloroquine can be of great importance as prophylactic medication for people living in and travelling to the affected area. Chloroquine is ubiquitously available, of low cost, and easy to administer. It may be considered for immediate use in the prevention and treatment of SARS-CoV infections.

Acknowledgments

We thank the colleagues of the laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical
Research, University of Leuven, Belgium, for helpful comments and discussion. This work was supported by a fellowship of the Flemish Fonds voor Wetenschappelijk Onderzoek (FWO) to Leen Vijgen, and by FWO-Grant G.0288.01.

References

[1] World Health Organization, 2003. Communicable Disease Surveillance and Response. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available from: <http://www.who.int/csr/sars/country/table2003_09_23/en/>(revised 26 September 2003).

[2] C. Drosten, S. Gunther, W. Preiser, S. van der Werf, H.R. Brodt, S. Becker, H. Rabenau, M. Panning, L. Kolesnikova, R.A. Fouchier, A. Berger, A.M. Burguierie, J. Cinatl, M. Eickmann, N. Escriou, K. Grywna, S. Kramme, J.C. Manuguerra, S. Muller, V. Rickerts, M. Sturmer, S. Vieth, H.D. Klenk, A.D. Osterhaus, H. Schmitz, H.W. Doerr, Identification of a novel coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med. 348 (2003) 1967–1976.

[3] T.G. Ksiazek, D. Erdman, C.S. Goldsmith, S.R. Zaki, T. Peret, S. Emery, S. Tong, C. Urbanbi, J.A. Comer, W. Lim, P.E. Rollin, S.F. Dowell, A.E. Ling, C.D. Humphrey, W.J. Shieh, J. Guarnier, C.D. Paddock, P. Rota, B. Fields, J. DeRisi, J.Y. Yang, N. Cox, J.M. Hughes, J.W. LeDuc, W.J. Bellini, L.J. Anderson, SARS Working Group, A novel coronavirus associated with severe acute respiratory syndrome, N. Engl. J. Med. 348 (2003) 1953–1966.

[4] T. Kuiken, R.A. Fouchier, M. Schutten, G.F. Rimmelzwaan, G. van Amerongen, D. van Riel, J.D. Laman, T. de Jong, G. van Doornum, W. Lim, A.E. Ling, P.K. Chan, J.S. Tam, M.C. Zambon, R. Gopal, C. Drosten, S. van der Werf, N. Escriou, J.C. Manuguerra, K. Stohr, J.S. Peiris, A.D. Osterhaus, Newly discovered coronavirus associated with severe acute respiratory syndrome, Lancet 362 (2003) 263–270.

[5] J.S. Peiris, S.T. Lai, L.L. Poon, Y. Guan, L.Y. Yam, W. Lim, J. Nicholls, W.K. Yee, W.W. Yan, M.T. Cheung, V.C. Cheng, K.H. Chan, D.N. Tsang, R.W. Yung, T.K. Ng, K.Y. Yuen, Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet 361 (2003) 1319–1325.

[6] F.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, R. Flick, J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drobet, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R.C. Brunham, M. Krafjen, M. Petric, D. Skowronska, C. Upton, R. Roper, The genome sequence of the SARS-associated coronavirus, Science 300 (2003) 1399–1404.

[7] K.S. Chan, S.T. Lai, C.M. Chu, E. Tsui, C.Y. Tam, M.M. Wong, M.W. Tse, T.L. Que, J.S. Peiris, J. Sung, V.C. Wong, K.Y. Yuen, Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study, Hong Kong Med. J. 9 (2003) 399–406.

[8] C.M. Chu, V.C. Cheng, I.F. Hung, M.M. Wong, K.H. Chan, K.S. Chan, R.Y. Kao, L.L. Poon, C.L. Wong, Y. Guan, J.S. Peiris, K.Y. Yuen, HKU/UCH SARS study group, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax 59 (2004) 252–256.

[9] J. Cinatl, M. Michaelis, M. Scholz, H.W. Doerr, Role of interferons in the treatment of severe acute respiratory syndrome, Expert. Opin. Biol. Ther. 4 (2004) 827–836.

[10] G. Zhaoiri, Antiviral treatment of SARS: can we draw any conclusions?, CMAJ 169 (2003) 1165–1166.

[11] J. Cinatl, B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus, Lancet 361 (2003) 2045–2046.

[12] C.J. Wu, J.T. Chan, C.M. Chen, H.P. Hsieh, D.R. Hwang, H.W. Liu, C.Y. Liu, H.W. Huang, S.C. Chen, C.F. Hong, R.K. Lin, Y.S. Chao, J.T. Hsu, Inhibition of severe acute respiratory syndrome coronavirus replication by nicosamide, Antimicrob. Agents Chemother. 48 (2004) 2693–2696.

[13] N. Yamamoto, R. Yang, Y. Yoshinaka, S. Amari, T. Nakano, J. Cinatl, H. Rabenau, H.W. Doerr, G. Hunsmann, A. Otaka, H. Tamaura, N. Fujii, N. Yamamoto, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun. 318 (2004) 719–725.

[14] E. Keyaerts, L. Vijgen, L. Chen, P. Maes, G. Hedenstierna, M. Van Ranst, Inhibition of SARS-coronavirus infection in vitro by S-nitroso-N-acetylpenicillamine, a nitric oxide donor compound, Int. J. Infect. Dis. 8 (2004) 223–226.

[15] A. Savarino, J.R. Boelaert, A. Cassone, G. Majori, R. Cauda, Effects of chloroquine on viral infections: an old drug against today’s diseases?, Lancet Infect. Dis. 3 (2003) 722–727.

[16] W.P. Tsai, P.L. Nara, H.F. Kung, S. Oroszlan, Inhibition of human immunodeficiency virus infectivity by chloroquine, AIDS Res. Hum. Retroviruses 6 (1990) 481–489.

[17] W.M. Partridge, J. Yang, A. Diagne, Chloroquine inhibits HIV-1 replication in human peripheral blood lymphocytes, Immunol. Lett. 64 (1998) 45–47.

[18] A. Savarino, L. Gennero, K. Sperber, J.R. Boelaert, The anti-HIV-1 activity of chloroquine, J. Clin. Virol. 20 (2001) 131–135.

[19] E.A. Kouroumalis, J. Koskinas, Treatment of chronic active hepatitis B (CAH B) with chloroquine: a preliminary report, Ann. Acad. Med. Singapore 15 (1986) 149–152.

[20] A.K. Singh, G.S. Sidhu, R.M. Friedman, R.K. Maheshwari, Mechanism of enhancement of the antiviral action of interferon against herpes simplex virus-1 by chloroquine, J. Interferon Cytokine Res. 16 (1996) 725–731.

[21] D. Blau, K. Holmes, Human Coronavirus HCoV-229E enters susceptible cells via the endocytic pathway, in: E. Lavi (Ed.), The Cytokine Res. 16 (1996) 725–731.

[22] B. Morgenstern, G. Bauer, P. Chandra, H. Rabenau, H.W. Doerr, G. Hunsmann, A. Otaka, H. Tamaura, N. Fujii, N. Yamamoto, HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus, Biochem. Biophys. Res. Commun. 318 (2004) 719–725.

[23] C.M. Chu, V.C. Cheng, I.F. Hung, M.M. Wong, K.H. Chan, K.S. Chan, R.Y. Kao, L.L. Poon, C.L. Wong, Y. Guan, J.S. Peiris, K.Y. Yuen, HKU/UCH SARS study group, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax 59 (2004) 252–256.

[24] J. Cinatl, M. Michaelis, M. Scholz, H.W. Doerr, Role of interferons in the treatment of severe acute respiratory syndrome, Expert. Opin. Biol. Ther. 4 (2004) 827–836.

[25] G. Zhaoiri, Antiviral treatment of SARS: can we draw any conclusions?, CMAJ 169 (2003) 1165–1166.
[25] C.J. Goodwin, S.J. Holt, S. Downes, N.J. Marshall. Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS, J. Immunol. Methods 179 (1995) 95–103.

[26] M.L. Ng, S.H. Tan, E.E. See, E.E. Ooi, A.E. Ling. Proliferative growth of SARS coronavirus in Vero E6 cells, J. Gen. Virol. 84 (2003) 3291–3303.

[27] G. Charmot, J.P. Coulaud. Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria), Med. Trop. 50 (1990) 103–108.

[28] F.A. Wollheim, A. Hanson, C. Laurell. Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels, Scand. J. Rheumatol. 7 (1978) 171–176.